BSGM BioSig Technologies, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

BSGM [NASD]

BioSig Technologies, Inc.

Healthcare | Medical Devices | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.76	Insider Own	8.70%	Shs Outstand	24.39M	Perf Week	-2.83%
Market Cap	206.78M	Forward P/E	38.92	EPS next Y	0.19	Insider Trans	1.45%	Shs Float	22.61M	Perf Month	-28.00%
Income	-39.50M	PEG	-	EPS next Q	-0.39	Inst Own	13.30%	Short Float	12.53%	Perf Quarter	39.26%
Sales	-	P/S	-	EPS this Y	-12.00%	Inst Trans	0.50%	Short Ratio	3.08	Perf Half Y	22.87%
Book/sh	0.62	P/B	11.61	EPS next Y	112.20%	ROA	-271.10%	Target Price	-	Perf Year	-19.46%
Cash/sh	0.54	P/C	13.34	EPS next 5Y	-	ROE	-327.00%	52W Range	2.36 - 12.43	Perf YTD	21.62%
Dividend	-	P/FCF	-	EPS past 5Y	6.20%	ROI	-	52W High	-42.08%	Beta	1.43
Dividend %	-	Quick Ratio	9.90	Sales past 5Y	-	Gross Margin	-	52W Low	205.08%	ATR	0.78
Employees	33	Current Ratio	10.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	33.49	Volatility	6.40% 8.65%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-41.10%	Profit Margin	-	Rel Volume	0.69	Prev Close	7.11
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	918.73K	Price	7.20
Recom	2.00	SMA20	-16.29%	SMA50	-24.73%	SMA200	7.31%	Volume	635,241	Change	1.27%

Mar-30-20

Initiated

ROTH Capital

Buy

Jul-10-20 01:15PM	BioSig Submits Application to Systems for Award Management (SAM) with U.S. Government GlobeNewswire
Jul-01-20 09:15AM	BioSig Technologies Inc. Appoints Tony Zook to the Board of Directors GlobeNewswire
Jun-29-20 08:18AM	BioSig Technologies, Inc Closes $17.5 Million Common Stock Offering GlobeNewswire +9.06%
Jun-24-20 09:20AM	BioSig Technologies, Inc. Announces $17.5 Million Common Stock Only Registered Direct Offering GlobeNewswire -21.94%
Jun-22-20 02:30PM	ViralClear Partners with Catalent on Potential Treatment for COVID-19 GlobeNewswire
Jun-17-20 07:55AM	ViralClear Opens Enrollment with First Patient Dosing in Phase II Human Trial of Anti-Viral MMPD Oral Solution for Treatment of COVID-19 GlobeNewswire +5.29%
Jun-08-20 03:02PM	Reminder - BioSig Subsidiary, ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-Viral Candidate for Treatment of COVID-19 GlobeNewswire +12.02%
Jun-05-20 09:10AM	ViralClear adds St. David's HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19 GlobeNewswire
Jun-04-20 09:25AM	BioSig Technologiess PURE EP System to be Presented in Heart Rhythm Society 2020 Science Sessions GlobeNewswire
Jun-03-20 11:45AM	BioSig Technologies Expands Intellectual Property Portfolio GlobeNewswire +7.59%
Jun-01-20 10:42AM	ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-viral Candidate for Treatment of COVID-19 GlobeNewswire +11.73%
May-28-20 08:40AM	Michael R. Dougherty Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc. GlobeNewswire -5.09%
May-20-20 10:12AM	ViralClear Closes $10.8 Million Equity Financing for Development of COVID-19 Broad-Spectrum Oral Anti-Viral Candidate Merimepodib GlobeNewswire
May-18-20 08:32AM	FDA Clears the Investigational New Drug Application to Enable the Phase II Trial of ViralClears Merimepodib, Oral Solution to Treat Adult Patients with Advanced COVID-19, to Proceed GlobeNewswire
May-14-20 08:15AM	ViralClear Publishes in F1000 Research In Vitro Data Demonstrating Synergy between Merimepodib and Remdesivir Against SARS-CoV-2, the Cause of COVID-19 GlobeNewswire
May-07-20 03:17PM	Michael Schmertzler Joins the Board of ViralClear Pharmaceuticals, a Majority-Owned Subsidiary of BioSig Technologies, Inc. GlobeNewswire
May-05-20 02:10PM	Biotech and Investment Veteran Dennis Purcell Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc. GlobeNewswire +6.35%
07:02AM	Could This Under-the-Radar Biotech Piggyback on Gilead's Remdesivir Success? Motley Fool
May-01-20 10:39AM	BioSig Resumes Clinical Activities with PURE EP System GlobeNewswire
Apr-30-20 09:20AM	ViralClear Submits In Vitro Data on Merimepodib and Remdesivir Synergistic Activity Against the COVID-19 Novel Coronavirus to a Peer-Reviewed Journal GlobeNewswire -13.30%
Apr-24-20 02:30PM	BioSig to Host Conference Call on Recent Developments of Subsidiary ViralClear and its Broad-Spectrum Oral Anti-Viral Candidate Merimepodib for the Treatment of COVID-19 GlobeNewswire +12.84%
09:25AM	BioSig Subsidiary ViralClear Submits Investigational New Drug Application to the FDA for Phase II Clinical Trials for Merimepodib, an Orally Administered Treatment for Patients with COVID-19 GlobeNewswire
Apr-23-20 09:15AM	ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19 Novel Coronavirus in F1000 Research GlobeNewswire +7.08%
Apr-21-20 02:36PM	Tony Zook Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc. GlobeNewswire
10:15AM	BioSig Subsidiary ViralClear Submits Application for Vicromax Through FDAs Coronavirus Treatment Acceleration Program (CTAP) to Seek Acceleration of its Planned Clinical Trials GlobeNewswire
Apr-17-20 02:07PM	BioSig Issues April 2020 Shareholder Update Letter GlobeNewswire +12.72%
01:27PM	New startup with local ties testing compound with Mayo Clinic to starve COVID-19 American City Business Journals
Apr-16-20 09:45AM	Mayo Clinic preparing to Commence Phase II FDA clinical trial for the treatment of COVID-19 with Vicromax GlobeNewswire
Apr-09-20 08:22AM	Positive Data Generated by Biosig Subsidiary ViralClear on Covid-19 Coronavirus Published in bioRxiv GlobeNewswire +10.94%
Apr-03-20 01:10PM	BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That May Treat COVID-19 GlobeNewswire +42.38%
Mar-31-20 08:45AM	Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc. GlobeNewswire -17.03%
Mar-25-20 07:52AM	BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell culture GlobeNewswire
Mar-22-20 08:31AM	Who Has Been Buying BioSig Technologies, Inc. (NASDAQ:BSGM) Shares? Simply Wall St.
Mar-10-20 08:05AM	Florida Cardiologist Zachariah P. Zachariah, M.D. Joins BioSig Technologies, Inc. Advisory Board GlobeNewswire
Mar-04-20 07:52AM	BioSig Appoints John W. Osborn, Ph.D. as Consultant on Autonomic Neuromodulation GlobeNewswire
Mar-03-20 12:20PM	BioSig to Webcast its Presentation at the Cowen and Companys 40th Annual Health Care Conference GlobeNewswire
Feb-26-20 08:33AM	BioSig to Present at the Cowen & Co. 40th Annual Health Care GlobeNewswire
Feb-25-20 03:25PM	BioSig Announces Closing of Public Offering of Common Stock GlobeNewswire
Feb-21-20 08:45AM	BioSig Announces $10 Million Public Offering of Common Stock GlobeNewswire -10.22%
07:46AM	The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion Benzinga
Feb-20-20 04:18PM	BioSig Announces Proposed Public Offering of Common Stock GlobeNewswire -6.25%
Feb-19-20 08:33AM	BioSig Completes 100th Patient Case with PURE EP(TM) System GlobeNewswire +13.74%
Jan-21-20 07:52AM	BioSig to Present at the 25th Annual International AF Symposium GlobeNewswire
Jan-16-20 07:52AM	BioSig to Commence Patient Cases at Mayo Clinic GlobeNewswire
Jan-14-20 07:52AM	BioSig Awarded Additional US Patent Claims for its PURE EP(TM) System GlobeNewswire
Dec-23-19 05:57AM	BioSig Technologies, Inc. (NASDAQ:BSGM): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
Dec-03-19 07:52AM	BioSig Technologies Announces New Collaboration on Development of Artificial Intelligence Solutions in Healthcare GlobeNewswire
Dec-02-19 03:40PM	BioSig Technologies Partners Mayo Clinic to Treat Arrhythmia Zacks
Nov-26-19 07:52AM	BioSig Technologies Signs Three New Licensing Agreements with Mayo Clinic GlobeNewswire
Nov-21-19 07:52AM	BioSig Commences Clinical Trial Enrollment for PURE EP System GlobeNewswire
Nov-18-19 07:52AM	BioSig Technologies Welcomes the Creation of New Bioelectronic Medicine Alliance GlobeNewswire
Nov-14-19 07:52AM	BioSig Technologies Issues November 2019 Shareholder Letter GlobeNewswire
Nov-07-19 07:52AM	BioSig Technologies Invests in Union Colleges Internship Program GlobeNewswire
Nov-06-19 07:52AM	Sasha Gentling, CFA Joins BioSig as Director of Business Development GlobeNewswire +8.14%
Oct-29-19 07:52AM	BioSig Appoints Andrew Ballou as Vice President of Investor Relations GlobeNewswire
Oct-24-19 11:02AM	Here's Why We're Watching BioSig Technologies's (NASDAQ:BSGM) Cash Burn Situation Simply Wall St.
Oct-15-19 07:52AM	BioSig Opens a Technology Development Office in Rochester, MN GlobeNewswire
Oct-10-19 07:52AM	BioSig to Participate at The 14th Annual International Symposium on Ventricular Arrhythmias: Pathophysiology & Therapy GlobeNewswire
Sep-30-19 07:52AM	BioSig to Present Clinical Observations at Venice Arrhythmias 2019 GlobeNewswire
Sep-26-19 07:52AM	Global Marketing and Strategy Leader Martha Pease Joins BioSig Board of Directors GlobeNewswire
Sep-16-19 08:09AM	BioSig Technologies-Mayo Clinic Ink Electrophysiology Deal Zacks
Sep-12-19 07:52AM	BioSig Technologies Signs a New Licensing Agreement with Mayo Clinic GlobeNewswire
Sep-09-19 01:06PM	BioSig Technologies, Inc. (NASDAQ:BSGM) Insiders Increased Their Holdings Simply Wall St.
Sep-05-19 07:52AM	BioSigs Subsidiary NeuroClear Technologies, Inc. Raises $3.7 million GlobeNewswire
Aug-01-19 09:00AM	BioSig Allowed Additional Foundational US Patent for its PURE EP(tm) System GlobeNewswire
Jul-24-19 07:52AM	Julie Stephenson Joins BioSig as Senior Director of Clinical Affairs GlobeNewswire
Jul-18-19 07:52AM	Olivier Chaudoir Joins BioSig as Director of Marketing GlobeNewswire
Jul-15-19 10:45AM	BioSig Technologies, Inc. to Receive 15 Units of PURE EP System from Manufacturer for Commercial Installation - Corrected Version GlobeNewswire
08:00AM	BioSig Technologies, Inc. to Receive 15 Units of PURE EP System from Manufacturer for Commercial Installation GlobeNewswire
Jul-11-19 07:52AM	Manasi Patwardhan Joins BioSig as Director of Strategic Planning GlobeNewswire
06:37AM	BioSig Technologies (NASDAQ:BSGM) Shareholders Have Enjoyed An Impressive 148% Share Price Gain Simply Wall St.
Jul-01-19 07:52AM	BioSig Technologies, Inc. Added to Membership of Russell 3000® Index GlobeNewswire
Jun-25-19 07:52AM	Samuel E. Navarro Appointed to BioSig Board of Directors GlobeNewswire
Jun-20-19 07:52AM	BioSig Technologies Issues June 2019 Shareholder Letter GlobeNewswire
Jun-10-19 09:17AM	BioSig Technologies Set to Join Russell 3000® Index GlobeNewswire +8.07%
Jun-06-19 07:52AM	BioSig Allowed a U.S. Patent for PURE EP Simulator GlobeNewswire +7.79%
Jun-03-19 07:52AM	BioSig Technologies Receives $4.6 Million in Cash Warrant and Option Exercises GlobeNewswire -11.83%
May-30-19 07:52AM	BioSig Technologies to Present at the 9th Annual LD Micro Invitational GlobeNewswire
May-23-19 07:52AM	BioSig Allowed First Key US Patent Claims for its PURE EP System GlobeNewswire
May-21-19 07:52AM	Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of Directors - Corrected Version GlobeNewswire
May-20-19 07:52AM	Dr. Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of Directors GlobeNewswire -8.14%
May-06-19 07:52AM	BioSig Technologies Completes Patient Cases at Indiana University GlobeNewswire
May-02-19 07:52AM	BioSigs Manuscript Accepted to IEEE Engineering in Medicine and Biology Conference 2019 GlobeNewswire
Apr-30-19 07:52AM	BioSig To Participate at Heart Rhythm Societys Scientific Sessions 2019 GlobeNewswire
Apr-16-19 07:52AM	BioSig Completes Successful Patient Cases at Greenville Memorial Hospital GlobeNewswire
Apr-09-19 07:52AM	Frank J. Quintero Joins BioSig Technologies Advisory Board GlobeNewswire
Mar-26-19 07:52AM	D.A. Wallach Joins BioSig Technologies Advisory Board GlobeNewswire
Mar-14-19 09:18AM	BioSig Technologies Completes Private Placement GlobeNewswire
Mar-12-19 08:45AM	LD Micro Virtual Conference Is Live, March 12th and 13th ACCESSWIRE
Mar-08-19 07:52AM	BioSig Technologies to Present at the LD Micro Virtual Conference GlobeNewswire
Mar-07-19 07:52AM	BioSig Technologies to Present at the 31st Annual ROTH Conference GlobeNewswire
Mar-06-19 07:52AM	BioSig Appoints Barry Keenan as Vice President of Engineering GlobeNewswire
Feb-26-19 07:52AM	BioSig Announces Expansion of Engineering Team GlobeNewswire
Feb-21-19 08:00AM	The Future Is Now; Med Tech Thats Changing Lives GlobeNewswire
Feb-20-19 07:52AM	BioSig Announces Successful First-In-Human Use of PURE EP System GlobeNewswire
Feb-12-19 07:52AM	BioSig Technologies Inc. Issues 2019 Shareholder Letter GlobeNewswire
Feb-05-19 07:52AM	BioSig Appoints John Kowalski to Lead Commercialization of PURE EP GlobeNewswire
Jan-31-19 10:23AM	Have Insiders Been Buying BioSig Technologies, Inc. (NASDAQ:BSGM) Shares? Simply Wall St.
Dec-19-18 08:00AM	Johnson & Johnson's Biosense Websters MaryAnn Edzards Joins BioSig GlobeNewswire
Dec-10-18 06:51AM	Moving Average Crossover Alert: Biosig Technologies, Inc. Zacks

BioSig Technologies, Inc., a medical technology company, engages in developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. The company's first product, PURE EPTM System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. This novel cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms. The company has partnered with Minnetronix on technology development and received FDA 510(k) clearance for the PURE EPTM System in August 2018. It is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments. The company has partnership with Albany Molecular Research Inc. for support in undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2, the virus that causes COVID-19 as a standalone treatment or in combination with other anti-viral agents or immune modulators. BioSig Technologies, Inc. was founded in 2009 and is headquartered in Westport, Connecticut.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LONDONER KENNETH L	Chief Executive Officer	May 29	Buy	9.26	4,000	37,020	1,282,758	May 29 11:30 AM
ZELDIS JEROME B	Director	May 28	Buy	10.49	1,000	10,489	107,944	May 28 10:58 AM
LONDONER KENNETH L	Chief Executive Officer	May 26	Buy	10.84	3,600	39,014	1,278,758	May 26 10:57 AM
Pease Martha	Director	Mar 23	Buy	3.00	3,000	9,000	9,437	Mar 25 02:55 PM
CHAUSSY STEVE	Chief Financial Officer	Mar 19	Buy	3.05	1,866	5,697	679,128	Mar 19 02:30 PM
Kowalski John M	VP of Sales	Mar 19	Buy	2.98	3,000	8,940	112,000	Mar 19 02:16 PM
Kowalski John M	VP of Sales	Mar 17	Buy	2.71	1,000	2,710	109,000	Mar 17 12:16 PM
CHAUSSY STEVE	Chief Financial Officer	Mar 16	Buy	2.61	4,000	10,440	677,262	Mar 16 01:35 PM
LONDONER KENNETH L	Chief Executive Officer	Mar 16	Buy	2.76	8,800	24,288	1,270,791	Mar 16 11:25 AM
Kowalski John M	VP of Sales	Mar 16	Buy	2.92	1,000	2,920	108,000	Mar 17 12:16 PM
LONDONER KENNETH L	Chief Executive Officer	Mar 16	Buy	2.70	4,367	11,786	1,275,158	Mar 16 02:22 PM
LONDONER KENNETH L	Chief Executive Officer	Jan 16	Option Exercise	5.23	100,000	523,000	1,358,393	Jan 21 08:14 PM
CHAUSSY STEVE	Chief Financial Officer	Jan 16	Option Exercise	5.23	12,000	62,760	684,830	Jan 21 08:08 PM
ODONNELL JEFFREY F	Director	Dec 18	Option Exercise	5.23	38,320	200,414	257,695	Dec 20 09:56 PM
Pease Martha	Director	Nov 22	Buy	6.25	1,300	8,125	6,437	Nov 26 09:48 AM
Pease Martha	Director	Nov 21	Buy	6.20	1,000	6,200	5,137	Nov 22 05:38 PM
Pease Martha	Director	Nov 20	Buy	6.20	1,000	6,200	4,137	Nov 22 05:38 PM
Pease Martha	Director	Nov 19	Buy	6.25	1,000	6,250	3,137	Nov 22 05:38 PM
NAVARRO SAMUEL E	Director	Nov 18	Buy	6.46	1,000	6,460	3,500	Nov 19 05:18 PM
Pease Martha	Director	Nov 18	Buy	6.55	1,000	6,550	2,137	Nov 19 05:14 PM
Pease Martha	Director	Nov 15	Buy	6.81	1,000	6,810	1,000	Nov 15 07:26 PM
Pease Martha	Director	Nov 15	Buy	6.65	137	911	1,137	Nov 19 05:14 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience